List of Excipients in Branded Drug TRANYLCYPROMINE SULFATE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Actavis Pharma Inc	TRANYLCYPROMINE SULFATE	tranylcypromine sulfate	0591-5590	ANHYDROUS CITRIC ACID
Actavis Pharma Inc	TRANYLCYPROMINE SULFATE	tranylcypromine sulfate	0591-5590	CARNAUBA WAX
Actavis Pharma Inc	TRANYLCYPROMINE SULFATE	tranylcypromine sulfate	0591-5590	CELLULOSE, MICROCRYSTALLINE
Actavis Pharma Inc	TRANYLCYPROMINE SULFATE	tranylcypromine sulfate	0591-5590	CROSCARMELLOSE SODIUM
Actavis Pharma Inc	TRANYLCYPROMINE SULFATE	tranylcypromine sulfate	0591-5590	D&C RED NO. 7

Generic Drugs Containing TRANYLCYPROMINE SULFATE

Company	Ingredient	NDC	Excipient
Alvogen Inc	tranylcypromine sulfate	47781-517	CALCIUM SULFATE
Alvogen Inc	tranylcypromine sulfate	47781-517	CARBOXYMETHYLCELLULOSE SODIUM
Alvogen Inc	tranylcypromine sulfate	47781-517	CELLULOSE, MICROCRYSTALLINE
Alvogen Inc	tranylcypromine sulfate	47781-517	CROSCARMELLOSE SODIUM
Alvogen Inc	tranylcypromine sulfate	47781-517	FD&C BLUE NO. 2

What are the Most Frequently-Used Excipients in TRANYLCYPROMINE SULFATE?

# Of NDCs	Excipient
1	CALCIUM SULFATE
1	CARBOXYMETHYLCELLULOSE SODIUM
5	CELLULOSE, MICROCRYSTALLINE
5	CROSCARMELLOSE SODIUM
4	DIBASIC CALCIUM PHOSPHATE DIHYDRATE

Excipient Strategy and Commercial Opportunities for Tranylcypromine Sulfate

Last updated: February 27, 2026

What are the excipient considerations for Tranylcypromine Sulfate?

Tranylcypromine sulfate, a monoamine oxidase inhibitor (MAOI) used in depression treatment, requires a specific excipient profile to optimize stability, bioavailability, and patient compliance. The formulation typically involves excipients that stabilize the active pharmaceutical ingredient (API) and facilitate manufacture, with key categories including fillers, binders, disintegrants, lubricants, and coatings.

How does excipient selection influence the drug's performance?

Excipients impact physical stability, solubility, absorption, and shelf-life. For Tranylcypromine sulfate tablets, common excipients include microcrystalline cellulose as a diluent, croscarmellose sodium as a disintegrant, magnesium stearate as a lubricant, and film coatings to mask taste and improve stability.

Typical excipient profile:

Excipients	Function	Specification Highlights
Microcrystalline cellulose	Filler	Provides tablet structure
Croscarmellose sodium	Disintegrant	Rapid swelling to aid dissolution
Magnesium stearate	Lubricant	Prevents sticking during compression
Hydroxypropyl methylcellulose	Coating agent	Protects API, masks taste

Optimizing the ratios and quality of excipients can improve bioavailability and shelf stability, key determinants for commercial success.

What are the key regulatory considerations for excipients in Tranylcypromine formulations?

Regulatory agencies such as the FDA and EMA require excipients to be pharmacopeia-grade or have equivalent quality. The excipients must be listed separately with acceptable specifications for heavy metals, microbial limits, and purity. Each excipient must also be compatible with the API to prevent interactions that could affect efficacy or safety.

What are the commercial opportunities in excipient development for Tranylcypromine sulfate?

The competitive landscape involves not only the active ingredient but also the formulation aspects. Opportunities include:

• Development of improved disintegrants to enable faster onset of action and better patient compliance.
• Use of novel coating technologies to extend shelf-life and improve taste masking.
• Formulating low-gluten or allergen-free excipients to meet specific patient needs, providing differentiation.
• Sourcing from high-quality excipient suppliers to ensure consistent manufacturing and regulatory compliance.

Advancements in excipient technology can allow firms to develop proprietary formulations, leading to brand differentiation and potential licensing deals.

How are excipient strategies affecting market entry and product lifecycle?

Innovative excipient use can facilitate regulatory approval by providing evidence of stability, safety, and efficacy. Once approved, proprietary excipient formulations can extend patent life indirectly through process patents or proprietary manufacturing protocols. Cost-effective sourcing of excipients also reduces production costs, improving margins.

What are the market dynamics for Tranylcypromine sulfate and related formulations?

The global pharmaceutical market for antidepressants, including MAOIs like Tranylcypromine, is growing at approximately 3-4% annually. Patent protections have expired for many formulations, prompting a shift toward generic manufacturers. Differentiation via excipient improvements can help companies maintain market share amid generic competition.

Key competitors include Teva, Mylan, and Sandoz, which produce generic versions with similar excipient profiles. Brand-name formulations from Pfizer and Lundbeck retain niche markets through formulation innovations.

Summary of commercial and formulation strategies

• Focus on excipient quality and compatibility to ensure stability and bioavailability.
• Invest in proprietary excipient or coating technologies to differentiate products.
• Align formulation choices with regulatory standards across target markets.
• Leverage excipient innovation to extend product lifecycle and mitigate generic competition.

Key Takeaways

• Excipient selection directly influences Tranylcypromine sulfate’s stability, absorption, and patient compliance.
• Regulatory compliance and excipient compatibility are critical to gaining approval.
• Innovation in excipient technologies offers market differentiation and potential for licensing.
• Cost management through sourcing and manufacturing efficiencies impacts profitability.
• Excipient strategy remains vital in the competitive landscape dominated by generic manufacturers.

FAQs

1. Can novel excipients improve bioavailability for Tranylcypromine sulfate?
Yes, novel disintegrants or solubilizing agents may enhance dissolution rates and absorption, possibly leading to more effective or faster-acting formulations.

2. What excipients are most commonly used in generic Tranylcypromine sulfate tablets?
Microcrystalline cellulose, croscarmellose sodium, magnesium stearate, and hydroxypropyl methylcellulose are typical due to their proven compatibility.

3. Are there excipient-related regulatory hurdles for Tranylcypromine formulations?
Regulatory agencies require excipients be pharmacopeia-grade or meet specific quality standards. Any novel excipient uses must be justified with data on safety and compatibility.

4. How can excipient choice affect patent strategy?
Innovative excipient formulations can be patented, providing exclusivity advantages beyond patent life on the API.

5. Is there a demand for allergen-free excipient options in antidepressant formulations?
Yes, especially for patients with sensitivities. Allergen-free excipients can differentiate products in a competitive market.

---

References

[1] U.S. Food and Drug Administration. (2022). Guidance for industry: excipients in drug products.
[2] European Medicines Agency. (2021). Guideline on pharmaceutical development of medicinal products for pediatric use.
[3] European Pharmacopoeia. (2020). Monographs on excipients and APIs.
[4] MarketWatch. (2023). Global antidepressants market report.
[5] Smith, J. (2021). Formulation strategies for monoamine oxidase inhibitors. Journal of Pharmaceutical Sciences.